Spyre Therapeutics, Inc. — Director's Dealing 2017

Apr 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-04-21

Reporting Person: Quinn Anthony (Director, interim Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-04-21	Employee Stock Option (right to buy)	$7.04	A	24000	Acquired	2027-04-20	Common Stock (24000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in three equal monthly installments beginning on May 21, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.